← Leaderboards
Zhihui Wang
Methodist Hospital Research Institute
$984,837
Attributed
$1,969,673
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $413.4K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,969,673 · 1
By mechanism
R01$1,969,673 · 1
Top collaborators
- Bulent Ozpolat5 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Kaifu Chen$6,629,635
- Cesar Augusto Arias$18,609,748
- Xuewu Liu$2,224,398
- Alessandro Grattoni$14,325,435
- Haifa Shen$7,162,956
Others in their field
Other Emerging Leaders on “Chemotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Olwen Hahn · Brigham And Women'S Hospital$13,557,463
- James Dale Berry · Brigham And Women'S Hospital$11,004,714
- Jessica Scott · Sloan-Kettering Inst Can Research$7,160,357
- Vera Hoffman · Reveal Pharma$6,103,452
Research focus
ChemotherapyAccountingChemotherapeutic AgentAntineoplastic AgentsAppropriate DoseAptamerAxl Receptor Tyrosine KinaseAcuteBindingBiologicalBiological MarkersBiological ProcessBiologyBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentCalmodulin-Dependent Protein Kinase IiiCancer SubtypesCancer TherapyCell CommunicationCell LineCellsChronic
Grant awards (5)
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$398,024
R01 · FY2025 · CA · contact PI
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$378,124
R01 · FY2024 · CA · contact PI
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$390,063
R01 · FY2023 · CA · contact PI
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$390,063
R01 · FY2022 · CA · contact PI
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$413,399
R01 · FY2021 · CA · contact PI